Micron perpetual contract specifications
MU on Aperi is a perpetual derivative linked to Micron. Its reviewed catalogue contract is xyz:MU on hyperliquid, using USDC collateral. This is price exposure; the contract does not deliver shares or ownership of the underlying asset.
Reviewed contract identity
- Product
- Micron (MU)
- Asset class
- Stocks
- Reviewed venue
- hyperliquid
- Native contract
- xyz:MU
- Native market ID
- hyperliquid.xyz.MU.USDC
- Collateral
- USDC
- Quote currency
- USDC
- Pricing model
- Native order book
- Classification
- Perpetual derivative
- Routing revision
- aperi-static-v1-2026-10-07
What this contract represents
Micron-linked perpetuals do not confer share or fund ownership, voting rights or guaranteed dividends. Corporate actions and reference adjustments follow the venue and deployer specification.
24/7 perpetual markets remain subject to market availability, venue halts, oracle limits and liquidity. Understand perpetuals and ownership.
Market data and availability
The terminal provides current public observations separately from this reviewed contract description. Prices, funding, leverage ceilings and quantity increments come from the native venue when available. Missing observations remain unavailable.
Order-book venues can expose quotes, books, trades and candle history, with individual source times. The catalogue may select another reviewed route under its liquidity policy; an existing position retains its original venue identity.
Funded trading on Aperi is currently disabled. Public data, account login and a connected wallet do not establish trading permission. Read our data methodology.
Collateral, costs and risk
The reviewed route uses USDC. Funds remain separate per venue; a combined portfolio does not provide shared collateral or automatic transfer authority. Aperi's proposed platform fee is 0.05% of notional, subject to builder qualification. Total costs also include venue fees, spread, slippage and funding.
Leverage can amplify losses and trigger liquidation. This is product documentation, not an investment recommendation. Risk disclosure · Collateral and fees · Funding and liquidation.